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Ovarioleukodystrophy – the co-occurrence of leukodystrophy and premature ovarian 
failure – is a rare presentation which is now recognised to be part of the clinical 
spectrum of vanishing white matter disease. We present the case of a lady with known 
seizures and neuroimaging changes consistent with leukoencephalopathy who 
presented with non-convulsive status epilepticus following initiation of hormone 
replacement therapy in the context of premature ovarian failure. Genetic testing 
confirmed she is a compound heterozygote for EIF2B-5 mutations; the gene encodes 
a subunit of eukaryotic translation initiation factor 2B. Mutations in EIF2B1-5 result in 
vanishing white matter disease. We highlight the importance of careful systemic review 
when investigating leukoencephalopathy and present a brief literature review of 
ovarioleukodystrophy.  




The finding of leukoencephalopathy on neuroimaging requires consideration of a 
broad range of differential diagnoses including Cerebral Autosomal Dominant 
Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), 
lysosomal storage disorders, mitochondrial disorders (1) and adrenoleukodystrophy in 
males. Despite extensive investigation however, the underlying diagnosis may remain 
elusive.  
 
In this clinical context, the emergence of an additional symptom or sign may be helpful 
in signposting the clinician to a diagnosis. We present the case of a woman who had 
pre-existing diagnoses of epilepsy and leukoencephalopathy but in whom the 
development of premature ovarian failure triggered screening for mutations in the 
eukaryotic translation initiation factor 2B subunit genes (EIF2B1-5); a variety of 
EIF2B1-5 subunit mutations have relatively recently been identified as causes of 
vanishing white matter (VWM) disease and ovarioleukodystrophy.  
 
CASE HISTORY 
Aged 19 years, our patient presented to another hospital with episodic neurological 
disturbance comprised of short-lived episodes of left-sided weakness preceded by 
paraesthesia. A single generalised tonic-clonic seizure was witnessed. A diagnosis of 
epileptic seizures was made and treatment commenced with sodium valproate and 
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levetiracetam. Neuroimaging changes consistent with leukoencephalopathy were 
noted and the patient was referred to our hospital for further investigation. 
 
Perinatal history was unremarkable. In infancy and early childhood there had been 
mild developmental delay – she did not crawl and was identified as having mild 
learning difficulty. Menarche occurred in her early teenage years and menstrual cycles 
had been regular. Febrile convulsions were reported in infancy. She attended a 
mainstream school but left without attaining formal qualifications. Subsequently, she 
worked in the family bakery. The past medical history was unremarkable aside from 
the diagnosis of epilepsy and migraine. 
 
Examination at that time revealed saccadic interposition of smooth pursuit, a postural 
upper limb tremor and a mild spastic quadriparesis. The patient was independent in 
activities of daily living and tremor improved following withdrawal of sodium valproate.  
 
Investigations undertaken to identify the underlying cause of leukoencephalopathy 
(Figure 1) but which were unremarkable included an abdominal ultrasound, nerve 
conduction studies, visual evoked potentials and Goldmann perimetry. Plasma and 
urinary amino acids, urinary organic acids, very long chain fatty acids, muscle biopsy 
and fibroblast culture with filipin staining were all normal. Peripheral blood screening 
for polymerase gamma gene (POLG), progressive external ophthalmoplegia twinkle 
helicase gene (C10orf2) and cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy (CADASIL) mutations was negative.  
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Aged 21 years and having been seizure free for 2.5 years, the menstrual cycle became 
irregular. Serum gonadotrophin levels confirmed premature ovarian failure. Karyotype 
analysis was normal. Hormone replacement therapy with the combined oral 
contraceptive pill was commenced but was rapidly complicated by the development of 
headaches, near continuous fortification spectra and elementary visual hallucinations 
(‘coloured blobs’) in the left visual field. There was a single generalised tonic-clonic 
seizure. EEG demonstrated rhythmic spike waves in the right posterior quadrant in 
keeping with the clinical suspicion of epilepsia partialis continua. Brain MRI confirmed 
restricted diffusion in the right occipital lobe (Figure 2). Initial treatment with 
benzodiazepines and increased levetiracetam was ineffective but seizure control was 
established following re-introduction of sodium valproate. Dual energy X-ray 
absorptiometry (DEXA) confirmed leukopenia with a low fracture risk. Her bone health 
is maintained vitamin D3 supplementation with a plan for repeat DEXA in 10 years. 
Following withdrawal of hormone replacement therapy, lamotrigine monotherapy has 
been successful. There has been no progression of symptoms or signs over the 
following 2 years. 
 
In view of the development of premature ovarian failure and the temporal relationship 
between the introduction of hormone replacement therapy and deterioration in control 
of migraine and epilepsy, an eIF2B-related disorder was considered. Blood samples 
were provided for whole gene screening by the patient and both parents. This 
confirmed compound heterozygote mutations of EIF2B5: maternal c.869>A, 
p.Arg299His and paternal c.913A>T, p.Met305Leu. Both mutations have been 
described in the context of vanishing white matter disease. 
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DISCUSSION 
eIF2B is a 5-subunit guanine nucleotide exchange factor which supports the activation 
of eIF2 by GTP binding. Activated, GTP-bound eIF2 is essential for the initiation of 
eukaryotic translation as active eIF2 binds methionine-tRNA in the first steps of 
translation (2). EIF2B gene mutations may reduce guanine nucleotide exchange 
activity on eIF2-GDP with associated increased susceptibility to physiological stress. 
Given however that eIF2B is ubiquitously expressed and regulates essential 
eukaryotic function, it remains unclear why disease expression is restricted to CNS 
white matter and ovarian follicles; in cerebral white matter, hyaluronan is known to 
accumulate in eIF2B-related disorders and may inhibit glial maturation and function 
(3).  
 
In the early 1990s, small paediatric series reported children with leukoencephalopathy 
who developed progressive ataxia and deteriorated in the context of head trauma or 
pyrexia (4) (5). Seizures and epilepsy were common. Progression of neurological 
disease was inexorable with the emergence of bulbar signs, optic atrophy and spastic 
quadriparesis. Death was reported to occur within 5 years of onset. Histopathology 
demonstrated normal grey matter and vacuolation of white matter with a paucity of 
astrocytes. Given the characteristic hypomyelination, the condition was initially 
described as childhood ataxia with cerebral nervous system hypomyelination (CACH) 
although the term ‘vanishing white matter syndrome’ has since become prevalent (6).  
 
Mutations in EIF2B1-5 were identified in VWM through genealogical study by 
haplotyping and radiation-hybrid mapping in patients known to have VWM (7); the 
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majority were found to have EIF2B5 gene mutations although changes in EIF2B2 were 
identified in others. 
 
A case series (8) reported four women aged 15 - 29 with premature ovarian failure 
(primary amenorrhoea, delayed puberty or early menarche), neurological decline, and 
characteristic changes on brain MRI. The similarity of brain MRI changes to those 
described in CACH/VWM was noted and the term ‘ovarioleukodystrophy’ coined. In 
one case where ovarian tissue was examined histopathologically, dysgenesis was 
confirmed. In another, brain histopathology confirmed hypomyelination without 
evidence of demyelination in keeping with the findings reported in CACH. Sequencing 
of EIF2B1-5 confirmed mutations in the EIFB2, EIFB4 or EIFB5 subunit genes in 7 out 
of 8 cases (9). At the time, none of these mutations had been described in CACH/VWM 
populations. 
 
Another series (10) presented data from a cohort of 16 patients presenting with adult-
onset eIF2B-related disorders. They reported a female preponderance (13:3 female 
to male) and a weak association of neurological decline with head injury or seizure (6 
of 16). Reported outcomes were highly variable; one case was asymptomatic whilst 
significant disability (11 of 14) or death (2 of 16) were also reported over the period of 
follow up (mean 11.2 years). 
 
Ovarioleukodystrophy is an extremely rare condition with fewer than twenty 
genetically-confirmed cases having been reported in the literature (11). Migraine and 
seizures have previously been reported and hormonal treatment has been associated 
with precipitating non-convulsive status in at least one other patient (12). 
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The diagnostic challenge facing the clinician investigating a patient with unexplained, 
progressive leukoencephalopathy is significant. We encourage practising neurologists 
and gynaecologists to be aware of the possibility of ovarioleucodystrophy and to liaise 
appropriately regarding cases where screening for EIF2B1-5 gene mutations may be 
of diagnostic relevance.  
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Figure Legends 
Figure 1: A - Coronal Fluid Attenuation Inversion Recovery (FLAIR) sequence brain 
MRI; B, C, D - Axial T2 Turbo Spin-Echo brain MRI (TSE). Cranial MRI demonstrated 
diffuse, symmetrical high T2 signal in the deep and subcortical white matter, without 
lobar predominance. The white matter was not swollen. There was symmetrical 
involvement of the extreme capsules but the external and internal capsules were 
spared. The basal ganglia, thalami and posterior fossa returned normal signal. The 
brain stem demonstrated volume loss as did the middle and superior cerebellar 
peduncles. Pallor in the middle cerebellar peduncles likely reflected Wallerian 
degeneration. The corpus callosum was also atrophic. 
 
Figure 2: A - Diffusion Weighted Single Shot Axial brain MRI; B, C, D - Axial T2 Turbo 
Spin-Echo (TSE) brain MRI demonstrate high T2 signal in the swollen cortex of the 
right posterior temporal, occipital and parietal lobes, with decreased diffusion but 
normal flow void in the right posterior cerebral artery. Cranial CT Angiography (not 
shown) confirmed normal intracranial arterial circulation. The appearances were 
considered to reflect seizure activity, mitochondrial disease having been excluded. 
Interval MRI showed resolution of the right temporal, occipital and parietal cortical 
oedema. 
Key points 
Mutations in EIF2B1-5 are a cause of vanishing white matter disease. 
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There is a spectrum of imaging changes associated with vanishing white matter 
disease; white matter vacuolation and loss are not prerequisites for the diagnosis. 
 
The association of leukoencephalopathy and ovarian failure should prompt 
consideration of screening for eIF2B-related disorders. 
 
Hormone replacement therapy may precipitate neurological deterioration and epileptic 
status in patients with eIF2B-related disorders. 
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